The headline reads as positive (95% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › CON
Concentra Group Holdings Parent (CON) stock analysis
BUY 49% confidence · analysed Oct 29, 2026
On Oct 29, 2026, our model rated Concentra Group Holdings Parent (CON) BUY with 49% confidence at a price of $40.59. That means most of the technical, fundamental, money-flow and news signals point to upside.
SectorHealthcare
IndustryMedical Care Facilities
Market cap5.18B
Analysed price$40.59
Technical picture
The 14-day RSI is 75, above 70, which is overbought: buyers have been very aggressive and a pause or pullback is common from here.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is only 0.6x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $24.51 and the swing low is $20.45; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The company reports a profit margin of 8.7% and revenue growth of +10.0%.
In its latest quarter it earned $0.52 per share, which beat the $0.42 analysts expected, with revenue +10.0% year over year.
Wall Street's average rating is 1.2 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $42.00.
The next earnings report is expected around Nov 5, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $40.59, a target of $42.00 (+3.5%) and a stop-loss at $38.69 (-4.7%).
That is a reward-to-risk ratio of about 0.7 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Nov 4, 2026 whatever the price does.
Entry$40.59
Target$42.00
Stop-loss$38.69
Reassess byNov 4, 2026
Research notes
CON’s bull case is accelerating earnings and revenue growth from its occupational-health network expansion, supported by recent clinic openings and optimistic analyst revisions; consensus remains “Buy” with an average target near $41.29. The bear case is valuation: shares trade around 24.2 times forward earnings versus an industry average near 18 times, while leverage, integration costs, overhead, and possible long-term volume pressure from remote work could constrain returns. The major recent catalyst was its latest earnings report, with EPS of $0.52 versus $0.42 expected and revenue of $606 million, followed by the stock reaching a new 52-week high around $40.64.
The model's one-paragraph read
Leans BUY — composite score +0.49 (BUY). Technicals: RSI 75.13, MACD bullish, price above SMA50. Fundamentals: margin 8.7%, revenue growth 10.0%. Financial results: YoY revenue +10.0%, last EPS surprise +23.8%, next earnings 2026-11-05. Smart Money Concepts: BOS bullish (trend continuation), price retesting a bullish order block. FinGPT news read: positive. Memory: 1 prior look(s). Internet research: CON’s **bull case** is accelerating earnings and revenue growth from its occupational-health network expansion, supported by recent clinic openings and optimistic analyst revisions; consensus remains “Buy” with an average target near $41.29. The **bear case** is valuation: shares trade around 24.2 times forward earnings versus an industry average near 18 times, while leverage, integration costs, overhead, and possible long-term volume pressure from remote work could constrain returns. The major recent catalyst was its latest earnings report, with EPS of $0.52 versus $0.42 expected and revenue of $606 million, followed by the stock reaching a new 52-week high around $40.64. Suggested levels: entry $40.59, target $42.0, stop-loss $38.69, exit by 2026-11-04 (exit before next earnings (2026-11-05) -- this signal doesn't price in that report).
Past ratings for CON
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 29, 2026 | BUY | 49% | $40.59 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on CON
Oct 29, 2026 · Equitable Bank increases prime rate
- Oct 29, 2026: Equitable Bank increases prime rate (PR Newswire)
Other Healthcare stocks we cover
COO · CRL · CVS · CYTK · DVA · EHC · ESTA · ETON · EVH · FTRE · HALO · HUM
Frequently asked questions
Is CON a buy right now?
As of Oct 29, 2026, our automated model rates Concentra Group Holdings Parent (CON) BUY with 49% confidence: most of the technical, fundamental, money-flow and news signals point to upside. This is a model output for education, not personal investment advice.
What is the price target for CON?
The model's most recent plan targets $42.00 with a stop-loss at $38.69, from an entry near $40.59.
When does Concentra Group Holdings Parent report earnings next?
The next earnings report is expected around Nov 5, 2026.
What does a BUY rating mean?
A BUY rating means most of the technical, fundamental, money-flow and news signals point to upside.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.